Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) today announced that a series of poster presentations by the Company’s research collaborators will be made at the …
In a research report released today, Canaccord Genuity analyst Neil Maruoka reiterated a Buy rating on Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) with a C$2.
